CuraTeQ Biologics Achieves Key Milestone with Health Canada Compliance

CuraTeQ Biologics, part of Aurobindo Pharma, has received compliance from Health Canada for its bevacizumab biosimilar, Bevqolva, used in cancer treatments. The formal marketing authorization confirms safety, efficacy, and quality. Two more biosimilar applications from CuraTeQ are awaiting Health Canada's review.

Aurobindo Pharma's subsidiary CuraTeQ Biologics has secured a significant regulatory approval for its bevacizumab biosimilar, known as Bevqolva, from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate.

The received compliance notice is a testament to the biosimilar's adherence to rigorous safety, efficacy, and quality standards, aligning with those of the reference drug Avastin, marketed by Roche/Genentech. This approval paves the way for Bevqolva in the Canadian oncology market.

CuraTeQ Biologics is advancing in its regulatory journey with Health Canada, with two more biosimilar applications currently under examination.